RegeneRx Biopharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Rockville MD United States (2002)

Organization Overview

First Clinical Trial
2006
NCT00311766
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

ReGenTree, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

thymosin beta-4 (12 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 1)

Dry Eye Syndromes (Phase 3)

Epidermolysis Bullosa (Phase 2)

Infarction (Phase 2)

Ischemia (Phase 1)

Keratoconjunctivitis Sicca (Phase 3)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 1)

Pressure Ulcer (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Syndrome (Phase 3)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 1